Table 6.
Genotype distribution of genes encoding proteins involved in type 2 diabetes and cardiovacular disease in adolescent girls with polycystic ovary syndrome and healthy controls
| Gene | Genotype | Cases (n = 44) | Controls (n = 50) | P | OR (95% CIs);P |
|---|---|---|---|---|---|
| CAPN10 (Calpain-10) | UCSNP44 (rs2975760) | 0.535 | |||
| TT | 33 (75%) | 34 (68%) | 1a | ||
| TC | 11 (25%) | 15 (30%) | 0.76 (0.30-1.88); 0.547 | ||
| CC | 0 (0%) | 1 (2%) | NC | ||
| TC + CC | 11 (25%) | 16 (32%) | 0.71 (0.29-1.75); 0.454 | ||
| Allele frequency | 0.387 | ||||
| T | 77 (88%) | 83 (83%) | 1a | ||
| C | 11 (12%) | 17 (17%) | 0.70 (0.31-1.58); 0.387 | ||
| UCSNP43 (rs3792267) | 0.771 | ||||
| GG | 29 (66%) | 33 (66%) | 1a | ||
| GA | 13 (29.5%) | 16 (32%) | 0.93 (0.38-2.24); 0.862 | ||
| AA | 2 (4.5%) | 1 (2%) | 2.28 (0.20-26.42); 0.602 | ||
| GA + AA | 15 (34%) | 17 (34%) | 1.00 (0.43-2.36); 0.993 | ||
| Allele frequency | 0.817 | ||||
| G | 71 (80.7%) | 82 (82%) | 1a | ||
| A | 17 (19.3%) | 18 (18%) | 1.09 (0.52-2.28); 0.817 | ||
| UCSNP19 (rs3842570) | 0.314 | ||||
| Ins/Ins | 10 (22.8%) | 16 (32%) | 1a | ||
| Del/Ins | 28 (63.6%) | 24 (48%) | 1.87 (0.72-4.88); 0.200 | ||
| Del/Del | 6 (13.6%) | 10 (20%) | 0.96 (0.27-3.47); 0.950 | ||
| Del/Ins + Del/Del | 34 (77.2%) | 34 (68%) | 1.79 (0.72-4.47); 0.211 | ||
| Allele frequency | 0.841 | ||||
| Ins | 48 (54.6%) | 56 (56%) | 1a | ||
| Del | 40 (45.4%) | 44 (44%) | 1.06 (0.60-1.89); 0.841 | ||
| UCSNP63 (rs5030952) | 0.160 | ||||
| CC | 37 (84.1%) | 36 (72%) | 1a | ||
| CT | 7 (15.9%) | 14 (28%) | 0.49 (0.18-1.35); 0.160 | ||
| TT | 0 (0%) | 0 (0%) | NC | ||
| Allele frequency | 0.189 | ||||
| C | 81 (92.1%) | 86 (86%) | 1 a | ||
| T | 7 (7.9%) | 14 (14%) | 0.53 (0.20-1.38); 0.189 | ||
| INSR (insulin receptor) | Exon17 C/T (rs1799817) | 0.437 | |||
| TT | 22 (50%) | 21 (42%) | 1a | ||
| CT | 22 (50%) | 29 (58%) | 0.72 (0.32-1.64); 0.437 | ||
| CC | 0 (0%) | 0 (0%) | NC | ||
| Allele frequency | 0.538 | ||||
| T | 66 (75%) | 71 (71%) | 1a | ||
| C | 22 (25%) | 29 (29%) | 0.82 (0.43-1.56); 0.538 | ||
| Exon12 G/A (rs2229434) | 1.000 | ||||
| GG | 43 (97.7%) | 49 (98%) | 1 a | ||
| GA | 1 (2.3%) | 1 (2%) | 1.14 (0.07-18.78); 1.000 | ||
| AA | 0 (0%) | 0 (0%) | NC | ||
| Allele frequency | 1.000 | ||||
| G | 87 (98.9%) | 99 (99%) | 1a | ||
| A | 1 (1.1%) | 1 (1%) | 1.14 (0.07-18.47); 1.000 | ||
| Exon12 G/C (rs2229430) | 1.000 | ||||
| GG | 43 (97.7%) | 49 (98%) | 1a | ||
| GC | 1 (2.3%) | 1 (2%) | 1.14 (0.07-18.47); 1.000 | ||
| CC | 0 (0%) | 0 (0%) | NC | ||
| Allele frequency | 1.000 | ||||
| G | 87 (98.9%) | 99 (99%) | 1a | ||
| C | 1 (1.1%) | 1 (1%) | 1.14 (0.07-18.47); 1.000 | ||
| SERPINE1 (Plasminogen activator inhibitor-1, PAI-1) | 4G/5G (-675 ins/delG) (rs1799817) | 0.589 | |||
| 4G/4G | 7 (16%) | 12 (24%) | 1a | ||
| 4G/5G | 24 (54.5%) | 26 (52%) | 1.58 (0.54-4.68); 0.405 | ||
| 5G/5G | 13 (29.5%) | 12 (24%) | 1.86 (0.55-6.28); 0.317 | ||
| 4G/5G + 5G/5G | 37 (84%) | 38 (76%) | 1.70 (0.59-4.71); 0.330 | ||
| Allele frequency | 0.350 | ||||
| 4G | 38 (43.2%) | 50 (50%) | 1a | ||
| 5G | 50 (56.8%) | 50 (50%) | 1.32 (0.74-2.34); 0.350 |
OR, odds ratio; CIs, confidence intervals.
aReference genotype/allele.
NC, Not Calculated